Bristol-Myers Squibb Company (BMY) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 2:00 PM EDT
Company Participants
Charles Triano – SVP & Head of Investor Relations
Cristian Massacesi – Executive VP, Chief Medical Officer & Head of Development
Conference Call Participants
Asad Haider – Goldman Sachs Group, Inc., Research Division
Presentation
Asad Haider
Goldman Sachs Group, Inc., Research Division
Terrific. We are just about in time. So let’s keep moving and kick off with the next session, Bristol-Myers, I am very excited to have Cristian Massacesi, CMO and Chuck Triano, SVP and Head of IR. Welcome, both. Thank you for being here. Great to be here.
Charles Triano
SVP & Head of Investor Relations
Great to be here.
Question-and-Answer Session
Asad Haider
Goldman Sachs Group, Inc., Research Division
So Cristian, I know that there’s a lot to talk about, but maybe we can start at 10,000 feet at a high level. We’ve noted that Bristol has been performing very well from a commercial execution perspective. But I think what investors are most focused on is a very consequential slate of clinical catalysts readouts that are coming up in the fourth quarter and maybe potentially even beyond that in the broader pipeline. And so we’re going to try and drill into a lot of the key programs here. But before we do that, I just want to kind of give you the opportunity to make any high-level comments on what you’ve been spending your time on and what you’re most excited about.
Cristian Massacesi
Executive VP, Chief Medical Officer & Head of Development
Thank you for the question. There are 3, 4 things that I spend — I joined BMS 10 months ago, most of the time. The first was, as you said, the short-term catalysts and be sure that we have been able to derisk all
